Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;54(4):769-777.
doi: 10.1016/j.otc.2021.05.002. Epub 2021 Jun 5.

Biologics for the Treatment of Recurrent Respiratory Papillomatosis

Clint T Allen  1
Affiliations
Review

Biologics for the Treatment of Recurrent Respiratory Papillomatosis

Clint T Allen. Otolaryngol Clin North Am. 2021 Aug.

Abstract

This article aims to educate readers on adjuvant therapies for recurrent respiratory papillomatosis (RRP). Although antivirals are injected locally into papillomas as an adjuvant treatment, new biologics targeting vascular endothelial growth factor or induction of human papillomavirus (HPV)-specific immunity are gaining traction with demonstration of clinical benefit and mechanism of action in retrospective case series and prospective clinical trials. The future of RRP treatment, alone or in combination with surgery, lies in the careful clinical study of vascular and immune targeting agents that balance the risk of adverse events with the chance for elimination of HPV-infected cells.

Keywords: Bevacizumab; Cidofovir; Immunotherapy; Recurrent respiratory papillomatosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The author declares no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis. Otolaryngol Clin North Am. 2019;52(4):669–679. - PubMed
    1. Drutman SB, Haerynck F, Zhong FL, et al. Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis. Proc Natl Acad Sci U S A. 2019;116(38):19055–19063. - PMC - PubMed
    1. Attra J, Hsieh LE, Luo L, et al. Development of Human-Derived Cell Culture Lines for Recurrent Respiratory Papillomatosis. Otolaryngol Head Neck Surg. 2018;159(4):638–642. - PMC - PubMed
    1. Ahn J, Bishop JA, Akpeng B, Pai SI, Best SR. Xenograft model for therapeutic drug testing in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2015;124(2):110–115. - PMC - PubMed
    1. Archambault J, Melendy T. Targeting human papillomavirus genome replication for antiviral drug discovery. Antivir Ther. 2013;18(3):271–283. - PMC - PubMed

MeSH terms

Substances

Supplementary concepts